It's likely the first combination METFORMIN and dipeptidyl peptidase-4 (DPP-4) inhibitor (in this case, ONGLYZA) we'll consider using as it does not include the original formulation of METFORMIN, but instead uses the extended-release ("ER") formulation. The original formulation of METFORMIN is much more likely to promote diarrhea at the doses we'd like to use in most patients.
This combination medication, in Type 2 diabetics, will impact the fasting and postprandial (after eating) blood sugar ... and we don't expect it to lead to weight gain.
It's likely the first combination METFORMIN and dipeptidyl peptidase-4 (DPP-4) inhibitor (in this case, ONGLYZA) we'll consider using as it does not include the original formulation of METFORMIN, but instead uses the extended-release ("ER") formulation. The original formulation of METFORMIN is much more likely to promote diarrhea at the doses we'd like to use in most patients.
This combination medication, in Type 2 diabetics, will impact the fasting and postprandial (after eating) blood sugar ... and we don't expect it to lead to weight gain.
One of the press releases is here .